Fate Therapeutics Inc
Fate Therapeutics Inc (FATE) Straddle
FATE straddle scan found 5 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 52.2%.
Read more
Trading a FATE straddle lets you take a pure volatility position on Fate Therapeutics Inc without committing to a direction. Fate Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate FATE straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on FATE profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Fate Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the FATE straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the FATE straddle is the cleanest expression of that view. Our scanner prices every FATE straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a FATE straddle into a catalyst or short a FATE straddle to harvest decay, the options straddle setups that matter are all in one place.
| Feb 19, 2027 | 3.00 | $1.55 | 156 | 4% | 52.2% | $4.55 | $1.45 | 5 |
| Feb 19, 2027 | 4.00 | $2.50 | 156 | 4% | 47.0% | $6.50 | $1.50 | 3 |
| Feb 19, 2027 | 6.00 | $4.45 | 156 | 4% | 44.5% | $10.45 | $1.55 | 0 |
| Nov 20, 2026 | 5.00 | $3.03 | 65 | 4% | 44.4% | $8.03 | $1.98 | 51 |
| Nov 20, 2026 | 4.00 | $2.15 | 65 | 4% | 41.1% | $6.15 | $1.85 | 355 |
As of September 16, 2026
Find the right straddle before volatility moves
Track FATE straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→